Bilibili Inc vs Neurocrine Biosciences Inc — how do they compare? Bilibili Inc trades at $17.47 (market cap $7.65B), while Neurocrine Biosciences Inc trades at $158.57 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.2× Bilibili Inc's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.
| BILI | NBIX | |
|---|---|---|
Market Cap | $7.65B | $16.46B |
Sector | Media | Health |
52-Week High | $35.92 | $185.50 |
52-Week Low | $15.96 | $123.10 |
Enterprise Value | $5.49B | $16.48B |
Signals from Pluang's Aura AI — not financial advice
Bilibili (BILI) trades at $17.48, down 7.95% over 24 hours, reflecting bearish technical momentum. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.19 versus $0.17 expected, and revenue growth to $30.35 billion in 2025. Analyst sentiment remains overwhelmingly bullish with 20 buy ratings out of 24, supported by a $300 million share repurchase program announced June 24, 2026.
The outlook is positive given robust user engagement and advertising growth, but risks include competitive pressures and reliance on Chinese market dynamics. Valuation metrics like a P/E of 36.24 suggest premium pricing, requiring sustained execution to justify upside. Near-term focus is on Q2 2026 earnings due August 27, 2026, which could catalyze movement.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →